US Patent

US8367685 — Stable pharmaceutical compositions comprising a pyrimidine-sulfamide

Method of Use · Assigned to Actelion Pharmaceuticals Ltd · Expires 2028-10-04 · 2y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects stable pharmaceutical compositions that include the compound of a specific formula or its pharmaceutically acceptable salts, solvates, hydrates, or morphological forms.

USPTO Abstract

Stable pharmaceutical compositions include the compound of the below formula, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof:

Drugs covered by this patent

Opsumit (MACITENTAN) · AstraZeneca

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1445`	—	Opsumit

Patent Metadata

Patent number: US8367685
Jurisdiction: US
Classification: Method of Use
Expires: 2028-10-04
Drug substance claim: No
Drug product claim: Yes
Assignee: Actelion Pharmaceuticals Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.